Vertex Pharmaceuticals
VRTX
1,547 hedge funds and large institutions have $109B invested in Vertex Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 121 funds opening new positions, 628 increasing their positions, 582 reducing their positions, and 106 closing their positions.
22% more call options, than puts
Call options by funds: $881M | Put options by funds: $721M
14% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 106
8% more repeat investments, than reductions
Existing positions increased: 628 | Existing positions reduced: 582
0% less funds holding
Funds holding: 1,549 → 1,547 (-2)
0.21% less ownership
Funds ownership: 91.15% → 90.93% (-0.21%)
1% less capital invested
Capital invested by funds: $110B → $109B (-$804M)
12% less funds holding in top 10
Funds holding in top 10: 33 → 29 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Edgewood Management
Greenwich,
Connecticut
|
+$734M |
| 2 |
Jennison Associates
New York
|
+$409M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$338M |
| 4 |
BlackRock
New York
|
+$228M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$222M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFA
Mayflower Financial Advisors
Boston,
Massachusetts
|
-$350M |
| 2 |
Goldman Sachs
New York
|
-$338M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$262M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$213M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$187M |
VRTX Hedge Fund Activity: Q3 2024 in Review
1,547 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2024, worth a combined $109B — down 0.73% from $110B a quarter earlier.
Buyers outnumbered sellers: 121 funds opened new VRTX positions and 106 closed out — a net gain of 15 holders — while 628 added to existing stakes and 582 trimmed.
The largest buyer was Edgewood Management, adding an estimated $734M. The largest seller was Mayflower Financial Advisors, cutting an estimated $350M.
- 1,547 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2024, down from 1,549 in Q2 2024.
- Funds reported $109B of Vertex Pharmaceuticals stock for Q3 2024, down 0.73% quarter-over-quarter.
- 121 funds opened new Vertex Pharmaceuticals positions in Q3 2024 and 106 closed out, a net change of +15 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2024 was Edgewood Management, an estimated $734M added.
- The largest Vertex Pharmaceuticals seller in Q3 2024 was Mayflower Financial Advisors, an estimated $350M sold.
Based on aggregated 13F filings for Q3 2024.